

	<b>Oncologic Peritoneal Surgery Unit (Unidad de Cirugía Oncológica Peritoneal/UCOP).</b>
---	--

DAS-IM-028

<b>Service</b>	<b>Oncologic Peritoneal Surgery Unit</b>
<b>Responsible</b>	<b>M<sup>a</sup> Isabel Ramos Bernadó. Chief of UCOP</b>
<b>Introduction</b>	<p>The Moisés Broggi hospital is the referral center for Catalonia and other autonomous communities of Spain for advanced treatment of peritoneal carcinomatosis using the combination of radical surgical resection (cytoreductive surgery) and heated intraperitoneal chemotherapy (CRS + HIPEC), referred to as the “Sugarbaker procedure”.</p> <p>This innovative and complex therapeutic approach is carried out under the leadership of the Oncologic Peritoneal Surgery Unit (UCOP). The UCOP unit is classified as a high specialization team in Complex Surgical Oncology by the Catalanian Health Plan, and focuses its activities on the management of peritoneal surface malignancies and other advanced abdominal surgical oncology procedures.</p> <p>The surgical team is supported by a multidisciplinary group of health care professionals. The medical oncology component of its activities is supported by the Catalanian Institut of Oncology (ICO).</p> <p>The UCOP allowed the development of a Regional Carcinomatosis Program for the treatment of peritoneal metastases in Catalonia sponsored by the health authorities and part of the Oncology Master Plan of Catalonia.</p> <p>The Catalanian Regional Carcinomatosis Program is the busiest in Spain and among the most experienced in the world. Since its inception in 2006, UCOP has performed more than 1200 surgical procedures of CRS and HIPEC and an additional 1000 CRS procedures without HIPEC. It is one of the few high specialization teams whose results are externally validated by independent agencies and the health authorities of Catalonia assuring full transparency regarding outcomes. The efficacy and safety results obtained by UCOP are equivalent or superior to those published by other leading centers in the world in all of the peritoneal malignancies treated.</p>

DAS-IM-028

## Services

### Infrastructure

- 4 operating room days per week
- 12 hours of outpatient consultations per week
- Weekly surgical team clinical session
- Weekly Peritoneal Surface Malignancies multidisciplinary tumor board meeting

### Procedures and service lines

- Treatment of all tumor types with peritoneal metastases where benefit from CRS +HIPEC have been shown:
  - . Pseudomyxoma peritonei (PMP)
  - . Peritoneal mesothelioma
  - . Colorectal cancer (with peritoneal metastases)
  - . Advanced ovarian cancer (peritoneal metastases in primary disease and recurrent ovarian cancer)
  - . Gastric cancer (with peritoneal metastases or positive cytology)
  - . Sarcomatosis
  - . Peritoneal metastases from other causes and rare cancers
- Treatment of pleural and pulmonary manifestations of pseudomyxoma peritonei
- Complex Surgical Oncology: advanced abdominal malignancies requiring multivisceral resections for primary disease or recurrence

DAS-IM-028

- Laparoscopic cytoreductive (with HIPEC) surgery for limited peritoneal metastases
- Laparoscopic gastrectomy (with HIPEC) for gastric cancer with minimal peritoneal metastases
- Retroperitoneal sarcoma
- Pelvic exenteration with reconstruction of the urinary tract and/or pelvic floor and/or the perineum
- Surgical treatment of complex recurrent tumors
- Abdominal complications related to radiation therapy: intestinal obstruction, fistulas, and chronic infections

The UCOP uses its vast experience with peritonectomy procedures for surgical procedures requiring a complex approach such as advanced malignancies and cases requiring reconstruction or repair of the digestive or urinary tract.

#### The Surgical Team

- Pedro Barrios Sánchez MD, Associate Professor at the University of Barcelona. Surgical Oncologist. Leader of the Regional Carcinomatosis Program of Catalonia. Founding member of the Spanish society of peritoneal oncologic surgery (GECOP) and member of other national and international societies of surgical oncology and peritoneal surface malignancies. Prior educational stays at several international cancer centers: Memorial Sloan Kettering Cancer Center, New York; Presbyterian Hospital, Pittsburg; MD Anderson Cancer Center, Houston and the Washington Cancer Center, Washington DC. Author of numerous publications and organizer of numerous scientific meetings and courses in advanced surgical oncology.
- Lana Bijelic MD. Surgical oncologist, fellowship trained with Dr. Paul Sugarbaker at the Washington Cancer Center, the most recognized leader in peritoneal surface malignancies worldwide. Board certified by the American

DAS-IM-028

Board of Surgery. Co-leader of the Regional Carcinomatosis Program of Catalonia. Director of Research of UCOP. Author of more than 20 peer-reviewed publications in surgical oncology and invited speaker at numerous international conferences. Member of the Peritoneal Surface Malignancy Working Group of the Society of Surgical Oncology, USA.

- M<sup>a</sup> Isabel Ramos Bernadó MD. Surgical oncologist. Chief of UCOP
- Domenico Sabia. Surgical oncologist. Prior educational stays at the Washington Cancer Center and the National Cancer Institute of Milan (Peritoneal Carcinomatosis Unit directed by Dr. M. Deraco)
- Oriol Crusellas Maña. Surgical oncologist.

The surgical team is supported by numerous other specialists who have experience in specific aspects of management of patients undergoing surgery for peritoneal metastases or advanced oncologic resections: medical oncologists, anesthesiologists, pathologists, intensivists, endocrinologists, nutritionists and a case manager. Surgical patients treated within UCOP are admitted to a unit with specialized and experienced nurses and follow defined clinical pathways prior, during and after their stay in the hospital.

### **Technology**

UCOP utilizes the latest technical equipment for safe and efficient administration of heated intraperitoneal chemotherapy.

### **Research**

The surgeons forming part of UCOP are continuously engaged in research activities, performing prospective and retrospective clinical studies and have presented at numerous international conferences.

UCOP also participates in multi-institutional clinical trials and research collaborations. The currently active multi-

DAS-IM-028

institutional trials are:

- T4  
Multicenter randomized clinical trial to evaluate the safety and efficacy of HIPEC with Mitomycin C associated with surgery for the treatment of locally advanced colorectal cancer
- EuroPMP  
COST Action. European Cooperation in Science & Technology  
CA17101: European network on Pseudomyxoma Peritonei
- Accelerator European multicentric study  
Pseudomyxoma peritonei: building a European multicentric cohort to accelerate new therapeutic perspective  
Cancer Research UK (CRUK), Asociación Española contra el Cancer (AECC) & Associazione Italiana per la Ricerca sul Cancro (AIRC) (Consortium)

### Education

- Educational stays for surgeons and other health care professionals interested in complex surgical oncology and/or forming new peritoneal surface malignancies treatment units both nationally and internationally, especially from Latin America
- Part of the network of educational centers and the European School of Peritoneal Surface Malignancies of the European Society of Surgical Oncology (ESSO)
- Accredited to provide education to general surgery residents

DAS-IM-028

- Educational site for year 4<sup>o</sup> and 6<sup>o</sup> students of the University of Barcelona Medical School

**Make contact with**

clinical secretariat:  
[secretaria.clinica@csi.cat](mailto:secretaria.clinica@csi.cat)

Tel +34 935531200  
FAX 935572671